CA2657847A1 - Method for predicting protein aggregation and designing aggregation inhibitors - Google Patents
Method for predicting protein aggregation and designing aggregation inhibitors Download PDFInfo
- Publication number
- CA2657847A1 CA2657847A1 CA002657847A CA2657847A CA2657847A1 CA 2657847 A1 CA2657847 A1 CA 2657847A1 CA 002657847 A CA002657847 A CA 002657847A CA 2657847 A CA2657847 A CA 2657847A CA 2657847 A1 CA2657847 A1 CA 2657847A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- aggregation
- peptide
- residues
- identified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 104
- 230000002776 aggregation Effects 0.000 title claims abstract description 89
- 238000004220 aggregation Methods 0.000 title claims abstract description 89
- 230000004845 protein aggregation Effects 0.000 title claims abstract description 26
- 239000003112 inhibitor Substances 0.000 title claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 160
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 143
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 143
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 25
- 238000012360 testing method Methods 0.000 claims abstract description 23
- 238000004590 computer program Methods 0.000 claims abstract description 5
- 235000018102 proteins Nutrition 0.000 claims description 118
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 44
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 238000013461 design Methods 0.000 claims description 15
- 230000007423 decrease Effects 0.000 claims description 12
- 150000008574 D-amino acids Chemical class 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 108010067902 Peptide Library Proteins 0.000 claims description 8
- 230000033077 cellular process Effects 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 208000007153 proteostasis deficiencies Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 108010071690 Prealbumin Proteins 0.000 claims description 5
- 102000009190 Transthyretin Human genes 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 230000005847 immunogenicity Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 102000029797 Prion Human genes 0.000 claims description 3
- 230000003019 stabilising effect Effects 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 claims description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 2
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 102000014824 Crystallins Human genes 0.000 claims description 2
- 108010064003 Crystallins Proteins 0.000 claims description 2
- 102000012192 Cystatin C Human genes 0.000 claims description 2
- 108010061642 Cystatin C Proteins 0.000 claims description 2
- 102400000524 Fibrinogen alpha chain Human genes 0.000 claims description 2
- 101710137044 Fibrinogen alpha chain Proteins 0.000 claims description 2
- 108090001064 Gelsolin Proteins 0.000 claims description 2
- 102000004878 Gelsolin Human genes 0.000 claims description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 2
- 102000011782 Keratins Human genes 0.000 claims description 2
- 108010076876 Keratins Proteins 0.000 claims description 2
- 101710191666 Lactadherin Proteins 0.000 claims description 2
- 102100039648 Lactadherin Human genes 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 102400001156 Medin Human genes 0.000 claims description 2
- 101800003015 Medin Proteins 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- 108010057464 Prolactin Proteins 0.000 claims description 2
- 102000003946 Prolactin Human genes 0.000 claims description 2
- 102000008847 Serpin Human genes 0.000 claims description 2
- 108050000761 Serpin Proteins 0.000 claims description 2
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 2
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 2
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 claims description 2
- 102100035140 Vitronectin Human genes 0.000 claims description 2
- 108010031318 Vitronectin Proteins 0.000 claims description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 2
- 108700006666 betaIG-H3 Proteins 0.000 claims description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 235000010335 lysozyme Nutrition 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 108010054442 polyalanine Proteins 0.000 claims description 2
- 108010040003 polyglutamine Proteins 0.000 claims description 2
- 229920000155 polyglutamine Polymers 0.000 claims description 2
- 229940097325 prolactin Drugs 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000003001 serine protease inhibitor Substances 0.000 claims description 2
- 102100027670 Islet amyloid polypeptide Human genes 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 18
- 230000003993 interaction Effects 0.000 description 15
- 230000008569 process Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 230000006933 amyloid-beta aggregation Effects 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 3
- 230000003942 amyloidogenic effect Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XQONXPWVIZZJIL-UHFFFAOYSA-N 1-(4-chlorophenyl)cyclobutane-1-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1(C#N)CCC1 XQONXPWVIZZJIL-UHFFFAOYSA-N 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 206010002023 Amyloidoses Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108010001817 Endo-1,4-beta Xylanases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 101710186621 Glycine cleavage system transcriptional repressor Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 108010029660 Intrinsically Disordered Proteins Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 210000003644 lens cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 102220024746 rs199473444 Human genes 0.000 description 1
- 102220139548 rs61735306 Human genes 0.000 description 1
- 102220184859 rs772223730 Human genes 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000007645 synaptic failure Effects 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82155306P | 2006-08-04 | 2006-08-04 | |
| US60/821,553 | 2006-08-04 | ||
| PCT/GB2007/002789 WO2008015384A1 (en) | 2006-08-04 | 2007-07-24 | Method for predicting protein aggregation and designing aggregation inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2657847A1 true CA2657847A1 (en) | 2008-02-07 |
Family
ID=38573441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002657847A Abandoned CA2657847A1 (en) | 2006-08-04 | 2007-07-24 | Method for predicting protein aggregation and designing aggregation inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8290713B2 (enExample) |
| EP (1) | EP2047393A1 (enExample) |
| JP (1) | JP2009545756A (enExample) |
| KR (1) | KR20090047470A (enExample) |
| CN (1) | CN101501694B (enExample) |
| AU (1) | AU2007280282B2 (enExample) |
| CA (1) | CA2657847A1 (enExample) |
| EA (1) | EA016884B1 (enExample) |
| IL (1) | IL196551A (enExample) |
| SG (1) | SG173405A1 (enExample) |
| WO (1) | WO2008015384A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| SG10201706600VA (en) | 2005-11-30 | 2017-09-28 | Abbvie Inc | Monoclonal antibodies and uses thereof |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| GB2455102A (en) * | 2007-11-28 | 2009-06-03 | Cambridge Entpr Ltd | Protein Aggregation Prediction Systems |
| EP2278998A1 (en) | 2008-04-17 | 2011-02-02 | Declion Pharmaceuticals, Inc. | Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders |
| CN110187119B (zh) * | 2008-10-31 | 2022-07-29 | 耶鲁大学 | 子痫前期检测和治疗的方法和组合物 |
| WO2011047442A1 (en) * | 2009-10-23 | 2011-04-28 | Garvan Institute Of Medical Research | Modified variable domain molecules and methods for producing and using same |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| FI20105629A0 (fi) * | 2010-06-03 | 2010-06-03 | Estaja Oy | Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US20120108904A1 (en) * | 2010-10-20 | 2012-05-03 | Yong Ma | Cleaner for endoscope |
| CN103772487B (zh) * | 2012-10-24 | 2015-11-25 | 国家纳米科学中心 | 一种抑制人胰淀素聚集或毒性的多肽、试剂及其应用 |
| US9618524B2 (en) * | 2014-03-26 | 2017-04-11 | Plaxgen Inc. | Method, composition, isolation and identification of a plaque particle and related biomarker |
| CN104502219B (zh) * | 2014-12-18 | 2017-09-29 | 江苏大学 | 一种淀粉样多肽聚集抑制剂及其抑制效果评估和验证方法 |
| SG11201705275VA (en) * | 2015-01-06 | 2017-07-28 | Univ North Carolina State | Modeling ribosome dynamics to optimize heterologous protein production |
| GB201600176D0 (en) * | 2016-01-06 | 2016-02-17 | Cambridge Entpr Ltd | Method of identifying novel protein aggregation inhibitors based on chemical kinetics |
| BR112018014870A2 (pt) * | 2016-01-21 | 2018-12-11 | Protein Dynamic Solutions Llc | método e sistema para análise de dados espectrais |
| US10815271B2 (en) * | 2016-06-29 | 2020-10-27 | The Regents Of The University Of California | Structure-based peptide inhibitors of alpha-synuclein aggregation |
| CN106501550A (zh) * | 2016-12-09 | 2017-03-15 | 江苏大学 | 基于原子力显微镜氨基酸影响鱼蛋白聚集行为的评价方法 |
| CN111653310B (zh) * | 2020-06-29 | 2023-06-20 | 北京大学深圳研究生院 | 含二硫键多肽的结构预测方法及装置 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA004739B1 (ru) * | 1999-11-05 | 2004-08-26 | Эксоникс, Инк. | ПЕПТИДНЫЕ АНАЛОГИ И МИМЕТИКИ, ПОДХОДЯЩИЕ ДЛЯ ПРИМЕНЕНИЯ IN VIVO ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АНОМАЛЬНОЙ УКЛАДКОЙ БЕЛКОВ В АМИЛОИДНЫЕ ИЛИ АМИЛОИДПОДОБНЫЕ ОТЛОЖЕНИЯ, ИЛИ ИХ ПАТОЛОГИЧЕСКИЕ ПРЕДШЕСТВЕННИКИ, ОБОГАЩЕННЫЕ b-СКЛАДКАМИ |
| EP1646375A2 (en) * | 2003-06-23 | 2006-04-19 | Neurochem (International) Limited | Treatment of protein aggregation disorders |
| GB0325817D0 (en) | 2003-11-05 | 2003-12-10 | Univ Cambridge Tech | Method and apparatus for assessing polypeptide aggregation |
-
2007
- 2007-07-24 KR KR1020097002794A patent/KR20090047470A/ko not_active Ceased
- 2007-07-24 CN CN2007800290322A patent/CN101501694B/zh not_active Expired - Fee Related
- 2007-07-24 EA EA200970180A patent/EA016884B1/ru not_active IP Right Cessation
- 2007-07-24 US US12/376,233 patent/US8290713B2/en not_active Expired - Fee Related
- 2007-07-24 SG SG2011052834A patent/SG173405A1/en unknown
- 2007-07-24 AU AU2007280282A patent/AU2007280282B2/en not_active Ceased
- 2007-07-24 JP JP2009523338A patent/JP2009545756A/ja active Pending
- 2007-07-24 WO PCT/GB2007/002789 patent/WO2008015384A1/en not_active Ceased
- 2007-07-24 EP EP07789035A patent/EP2047393A1/en not_active Withdrawn
- 2007-07-24 CA CA002657847A patent/CA2657847A1/en not_active Abandoned
-
2009
- 2009-01-15 IL IL196551A patent/IL196551A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL196551A (en) | 2013-01-31 |
| SG173405A1 (en) | 2011-08-29 |
| EA016884B1 (ru) | 2012-08-30 |
| KR20090047470A (ko) | 2009-05-12 |
| EP2047393A1 (en) | 2009-04-15 |
| CN101501694A (zh) | 2009-08-05 |
| US8290713B2 (en) | 2012-10-16 |
| JP2009545756A (ja) | 2009-12-24 |
| WO2008015384A1 (en) | 2008-02-07 |
| HK1131239A1 (en) | 2010-01-15 |
| AU2007280282A1 (en) | 2008-02-07 |
| CN101501694B (zh) | 2011-11-30 |
| AU2007280282B2 (en) | 2012-02-02 |
| US20100160602A1 (en) | 2010-06-24 |
| IL196551A0 (en) | 2009-11-18 |
| WO2008015384A8 (en) | 2008-05-15 |
| EA200970180A1 (ru) | 2009-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007280282B2 (en) | Method for predicting protein aggregation and designing aggregation inhibitors | |
| Schweke et al. | An atlas of protein homo-oligomerization across domains of life | |
| Murray et al. | De novo designed protein inhibitors of amyloid aggregation and seeding | |
| Robin et al. | Continuous Automated Model EvaluatiOn (CAMEO)—Perspectives on the future of fully automated evaluation of structure prediction methods | |
| Yoon et al. | Detecting hidden sequence propensity for amyloid fibril formation | |
| Sommer et al. | Structure-guided isoform identification for the human transcriptome | |
| Lamb et al. | It’s in our blood: a glimpse of personalized medicine | |
| Di Francesco et al. | FORESST: fold recognition from secondary structure predictions of proteins. | |
| Fatafta et al. | A brief history of amyloid aggregation simulations | |
| Linh et al. | Impact of mutations at C-terminus on structures and dynamics of Aβ40 and Aβ42: a molecular simulation study | |
| Li et al. | Unraveling the interplay of extracellular domain conformational changes and parathyroid hormone type 1 receptor activation in class B1 G protein-coupled receptors: integrating enhanced sampling molecular dynamics simulations and markov state models | |
| Huang et al. | Unveiling medin folding and dimerization dynamics and conformations via atomistic discrete molecular dynamics simulations | |
| Tastan et al. | Comparison of stability predictions and simulated unfolding of rhodopsin structures | |
| Puławski et al. | Multiscale modeling of protofilament structures: A case study on insulin amyloid aggregates | |
| Jakubek et al. | Polyglutamine solution-state structural propensity is repeat length dependent | |
| Liang et al. | Structures and Dynamics of β-Rich Oligomers of ATTR (105–115) Assembly | |
| Betancourt | A reduced protein model with accurate native‐structure identification ability | |
| Heinze et al. | CASP10–BCL:: Fold efficiently samples topologies of large proteins | |
| HK1131239B (en) | Method for predicting protein aggregation and designing aggregation inhibitors | |
| Pantoja-Uceda et al. | The NMR structure and dynamics of the two-domain tick carboxypeptidase inhibitor reveal flexibility in its free form and stiffness upon binding to human carboxypeptidase B | |
| Duan et al. | Performance of Hybrid Strategies Combining MDockPP and AlphaFold2 in CAPRI Rounds 47–55 | |
| Ma et al. | Empirical and computational comparison of alternative therapeutic exon skip repairs for Duchenne muscular dystrophy | |
| Sharma et al. | Prediction of interface between regions of varying degrees of order or disorderness in intrinsically disordered proteins from dihedral angles | |
| Cianferoni et al. | Artificial Intelligence And First Principle Methods In Protein Redesign: A Marriage Of Convenience? | |
| Hassan et al. | Neurodegeneration Through the Lens of Bioinformatics Approaches: Computational Mechanisms of Protein Misfolding |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140724 |